Literature DB >> 10846084

Interactions between brain endothelial cells and human T-cell leukemia virus type 1-infected lymphocytes: mechanisms of viral entry into the central nervous system.

I A Romero1, M C Prevost, E Perret, P Adamson, J Greenwood, P O Couraud, S Ozden.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) is associated with a variety of clinical manifestations, including tropical spastic paraparesis or HTLV-1-associated myelopathy (TSP/HAM). Viral detection in the central nervous system (CNS) of TSP/HAM patients demonstrates the ability of HTLV-1 to cross the blood-brain barrier (BBB). To investigate viral entry into the CNS, rat brain capillary endothelial cells were exposed to human lymphocytes chronically infected by HTLV-1 (MT2), to lymphocytes isolated from a seropositive patient, or to a control lymphoblastoid cell line (CEM). An enhanced adhesion to and migration through brain endothelial cells in vitro was observed with HTLV-1-infected lymphocytes. HTLV-1-infected lymphocytes also induced a twofold increase in the paracellular permeability of the endothelial monolayer. These effects were associated with an increased production of tumor necrosis factor alpha by HTLV-1-infected lymphocytes in the presence of brain endothelial cells. Ultrastructural analysis showed that contact between endothelial cells and HTLV-1-infected lymphocytes resulted in a massive and rapid budding of virions from lymphocytes, followed by their internalization into vesicles by brain endothelial cells and apparent release onto the basolateral side, suggesting that viral particles may cross the BBB using the transcytotic pathway. Our study also demonstrates that cell-cell fusion occurs between HTLV-1-infected lymphocytes and brain endothelial cells, with the latter being susceptible to transient HTLV-1 infection. These aspects may help us to understand the pathogenic mechanisms associated with neurological diseases induced by HTLV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846084      PMCID: PMC112099          DOI: 10.1128/jvi.74.13.6021-6030.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  HTLV-I induced myeloneuropathy in WKAH rats: apoptosis and local activation of the HTLV-I pX and TNF-alpha genes implicated in the pathogenesis.

Authors:  O Ohya; U Tomaru; I Yamashita; T Kasai; K Morita; H Ikeda; A Wakisaka; T Yoshiki
Journal:  Leukemia       Date:  1997-04       Impact factor: 11.528

2.  SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics.

Authors:  J Greenwood; G Pryce; L Devine; D K Male; W L dos Santos; V L Calder; P Adamson
Journal:  J Neuroimmunol       Date:  1996-12       Impact factor: 3.478

3.  Expression of adhesion molecules and monocyte chemoattractant protein -1 (MCP-1) in the spinal cord lesions in HTLV-I-associated myelopathy.

Authors:  F Umehara; S Izumo; M Takeya; K Takahashi; E Sato; M Osame
Journal:  Acta Neuropathol       Date:  1996       Impact factor: 17.088

4.  Exposure of tumor necrosis factor-alpha to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin.

Authors:  M A Deli; L Descamps; M P Dehouck; R Cecchelli; F Joó; C S Abrahám; G Torpier
Journal:  J Neurosci Res       Date:  1995-08-15       Impact factor: 4.164

5.  Spontaneous proliferation of and cytokine production by T cells adherent to human endothelial cells in patients with human T-lymphotropic virus type I-associated myelopathy.

Authors:  T Nakamura; Y Nishiura; K Ichinose; S Shirabe; A Tsujino; H Goto; T Furuya; S Nagataki
Journal:  Intern Med       Date:  1996-03       Impact factor: 1.271

6.  High incidence of HAM/TSP-like symptoms in WKA rats after administration of human T-cell leukemia virus type 1-producing cells.

Authors:  S Kushida; H Mizusawa; M Matsumura; H Tanaka; Y Ami; M Hori; K Yagami; T Kameyama; Y Tanaka; A Yoshida
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

7.  Constitutive overexpression of the L-selectin gene in fresh leukemic cells of adult T-cell leukemia that can be transactivated by human T-cell lymphotropic virus type 1 Tax.

Authors:  M Tatewaki; K Yamaguchi; M Matsuoka; T Ishii; M Miyasaka; S Mori; K Takatsuki; T Watanabe
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

8.  Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1. off.

Authors:  J Greenwood; Y Wang; V L Calder
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

Review 9.  Cell adhesion molecules in HTLV-I infection.

Authors:  T Uchiyama; T Ishikawa; A Imura
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996

10.  A rat model of HTLV-I infection: development of chronic progressive myeloneuropathy in seropositive WKAH rats and related apoptosis.

Authors:  K Seto; M Abe; O Ohya; O Itakura; N Ishiguro; H Ikeda; A Wakisaka; T Yoshiki
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

View more
  23 in total

1.  Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway.

Authors:  Nancy Q Liu; Albert S Lossinsky; Waldemar Popik; Xia Li; Chandrasekhar Gujuluva; Benjamin Kriederman; Jaclyn Roberts; Tatania Pushkarsky; Michael Bukrinsky; Marlys Witte; Martin Weinand; Milan Fiala
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 2.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

Review 3.  Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology.

Authors:  Máiria A Deli; Csongor S Abrahám; Yasufumi Kataoka; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 4.  Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions.

Authors:  Françoise Roux; Pierre-Olivier Couraud
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 5.  Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.

Authors:  Céline Passeleu-Le Bourdonnec; Pierre-Alain Carrupt; Jean Michel Scherrmann; Sophie Martel
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

6.  Autoimmunity due to molecular mimicry as a cause of neurological disease.

Authors:  Michael C Levin; Sang Min Lee; Franck Kalume; Yvette Morcos; F Curtis Dohan; Karen A Hasty; Joseph C Callaway; Joseph Zunt; Dominic Desiderio; John M Stuart
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

7.  Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo.

Authors:  Guangyong Ma; Jun-Ichirou Yasunaga; Koichi Ohshima; Tadashi Matsumoto; Masao Matsuoka
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

Review 8.  Pathogenesis of human immunodeficiency virus-induced neurological disease.

Authors:  Andrew V Albright; Samantha S Soldan; Francisco González-Scarano
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

9.  Role of the human T-cell leukemia virus type 1 PTAP motif in Gag targeting and particle release.

Authors:  Irene J Dorweiler; Susan J Ruone; Huating Wang; Richard W Burry; Louis M Mansky
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms.

Authors:  Grace S L Teo; James A Ankrum; Roberta Martinelli; Sarah E Boetto; Kayla Simms; Tracey E Sciuto; Ann M Dvorak; Jeffrey M Karp; Christopher V Carman
Journal:  Stem Cells       Date:  2012-11       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.